Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Serratus Posterior Superior Intercostal Planblokkering versus Intratekal Morfin ved VATs

1. oktober 2026 oppdatert av: Cengiz KAYA, Ondokuz Mayıs University

Sammenligning av effektene av Serratus Posterior Superior Intercostal Plane Block og intratekal morfin på postoperativ akuttsmerte hos pasienter som gjennomgår videoassistert torakoskopisk kirurgi

This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.

The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.

The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.

Studieoversikt

Detaljert beskrivelse

This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.

Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.

Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.

The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.

Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.

This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.

Studietype

Intervensjonell

Registrering (Faktiske)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Samsun
      • Atakent, Samsun, Tyrkia (Türkiye), 55270
        • Ondokuz Mayis University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 75 years
  • American Society of Anesthesiologists physical status I to III
  • Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy

Exclusion Criteria:

  • Refusal to participate
  • Pregnancy
  • Morbid obesity (body mass index greater than 40 kg per square meter)
  • Allergy to study medications
  • Neuropsychiatric disorders, cognitive impairment, or inability to communicate
  • History of substance abuse
  • Active systemic infection or infection at the planned injection site
  • Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
  • Chronic pain syndrome or ongoing chronic pain treatment
  • Emergency surgery or previous ipsilateral VATS or thoracotomy
  • Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
  • Anticipated need for postoperative mechanical ventilation.
  • Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intrathecal Morphine

Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia.

Eksperimentell: Serratus Posterior Superior Intercostal Plane Block

Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine.

Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
Tidsramme: 24 hours

Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia.

24 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
Tidsramme: 12 hours

Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents

12 hours
Postoperative pain scores
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity.

0, 3, 6, 12, 18, and 24 hours postoperatively
Time to first patient-controlled analgesia demand
Tidsramme: 24 hours

Time from postoperative admission to the first PCA morphine demand.

24 hours
Quality of recovery score
Tidsramme: Preoperative baseline, 24 hours postoperatively, and at discharge

Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery.

Preoperative baseline, 24 hours postoperatively, and at discharge
Postoperative nausea and vomiting
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide.

0, 3, 6, 12, 18, and 24 hours postoperatively
Sedation level
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli.

0, 3, 6, 12, 18, and 24 hours postoperatively
Respiratory depression
Tidsramme: 24 hours

Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute

24 hours
Pruritus
Tidsramme: 0, 3, 6, 12, 18, and 24 hours postoperatively

Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms.

0, 3, 6, 12, 18, and 24 hours postoperatively
Block-related complications
Tidsramme: Up to 30 days postoperatively

Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions.

Up to 30 days postoperatively
Postoperative complications
Tidsramme: 30 days

Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications.

30 days
Remifentanil consumption
Tidsramme: Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Rescue analgesia requirement
Tidsramme: 24 hours

Incidence of patients requiring additional analgesia beyond patient-controlled analgesia

24 hours
Incidence of postoperative nausea and/or vomiting
Tidsramme: 24 hours postoperatively

Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV.

24 hours postoperatively
Propofol consumption
Tidsramme: Intraoperative period (from induction to end of surgery), up to 4 hours

Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg).

Intraoperative period (from induction to end of surgery), up to 4 hours
Area under the numeric rating scale-time curve
Tidsramme: 0 to 24 hours postoperatively

The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden.

0 to 24 hours postoperatively
Comprehensive Complication Index
Tidsramme: Up to 30 days postoperatively

Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity.

Up to 30 days postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. april 2026

Primær fullføring (Faktiske)

15. august 2026

Studiet fullført (Faktiske)

15. september 2026

Datoer for studieregistrering

Først innsendt

9. april 2026

Først innsendt som oppfylte QC-kriteriene

16. april 2026

Først lagt ut (Faktiske)

20. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere